Atara Biotherapeutics 배당금 및 환매

배당금 기준 확인 0/6

Atara Biotherapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

-102.3%

환매 수익률

총 주주 수익률	-102.3%
미래 배당 수익률	18.9%
배당금 성장	n/a
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
지급 비율	n/a

최근 배당금 및 환매 업데이트

업데이트 없음

Recent updates

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Nov 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Sep 06

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Jul 21

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

Jul 03

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

May 14

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

May 11

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Feb 06

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Oct 17

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

May 18

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Feb 13

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%

Nov 22

EMA panel backs approval of Atara's Ebvallo for transplant complication

Oct 14

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 ATRA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: ATRA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Atara Biotherapeutics 시장 대비 배당 수익률

ATRA 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (ATRA)	n/a
시장 하위 25% (US)	1.4%
시장 상위 25% (US)	4.3%
업계 평균 (Biotechs)	2.3%
애널리스트 예측 (ATRA) (최대 3년)	18.9%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ATRA 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ATRA 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ATRA 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: ATRA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Atara Biotherapeutics 배당금 및 환매

배당금 기준 확인 0/6

주요 정보

최근 배당금 및 환매 업데이트

Recent updates

New minor risk - Profitability

Consensus revenue estimates increase by 14%

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Atara Biotherapeutics, Inc. Appoints Eric Hyllengren as Chief Operating Officer

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Surges 34% Yet Its Low P/S Is No Reason For Excitement

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $36 million.

Insufficient new directors

Consensus revenue estimates decrease by 15%, EPS upgraded

Consensus EPS estimates fall by 52%, revenue upgraded

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Atara Biotherapeutics, Inc. Announces CEO Changes, Effective September 9, 2024

New major risk - Share price stability

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Stock Catapults 34% Though Its Price And Business Still Lag The Industry

Price target decreased by 71% to US$30.33

Atara Biotherapeutics Announces U.S. Fda Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-Cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics: An Underestimated Contender In Autoimmune Diseases CAR-T Cell Therapy

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

President notifies of intention to sell stock

Consensus revenue estimates increase by 17%

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates increase by 117%

Price target decreased by 13% to US$4.20

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Consensus revenue estimates increase by 50%

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Price target increased by 17% to US$4.83

Consensus revenue estimates increase by 33%

Independent Director recently bought US$101k worth of stock

Consensus revenue estimates decrease by 27%

Price target decreased by 57% to US$6.40

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Share price stability

Price target decreased by 8.1% to US$14.82

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Revenue and earnings growth

Price target increased by 15% to US$18.48

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Consensus revenue estimates fall by 21%

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

Price target decreased by 13% to US$16.13

President recently sold US$61k worth of stock

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

Consensus revenue estimates fall by 55%

Consensus revenue estimates fall by 61%

Price target decreased by 20% to US$14.74

Price target decreased by 13% to US$16.43

Atara Biotherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 11%, EPS upgraded

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%